Macular Ganglion Cell Analysis (GCA) of the Cirrus HD-OCT in Glaucoma

Exclusion Criteria

• •Ophthalmic:
• •Best corrected visual acuity in either eye worse than 20/40 on a Snellen chart or on a Snellen equivalent acuity chart.
• •Refractive error outside -12.00D to +8.00D spherical range or \>-3.00D cylinder.
• •Previous vitreoretinal surgery in study eye.
• •Vitreoretinal traction or epiretinal membrane in the study eye.
• •Any active infection of anterior or posterior segments.
• •Evidence of diabetic retinopathy, diabetic macular edema, or other vitreoretinal disease in the study eye upon dilated examination, or upon evaluation of retinal photos.
• •Systemic:
• •History of diabetes, leukemia, AIDS, uncontrolled systemic hypertension, dementia or multiple sclerosis.
• •A life threatening or debilitating disease.
• •Participation in any study involving a non-FDA approved investigational drug (IND) within the past month, or ongoing participation in a study with a non-FDA approved or cleared investigational device (IDE).
• •Current or recent (within the past 14 days) use of an agent with photosensitizing properties by any route (e.g., Visudyne®, ciprofloxacin, Bactrim®, doxycycline, etc.).
• •Concomitant use of hydrochloroquine and/or chloroquine.